Atlas Trials

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Clinical trial NCT07484022 · RECRUITING

Trial details

NCT number
NCT07484022
Sponsor
Generate Biomedicines
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Urothelial CancerMetastatic Urothelial Carcinoma
Start date
2026-06-01
Primary completion
2027-06-01
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.